Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trial
Schwentner L, Janni W, Kiechle M, Härtl K, Weissenbacher T, Friedl T, Huober J, Scholz C, Wischnik A, Forstbauer H, Rack B, Eichler M, Singer S, Harbeck N, Fink V. Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trial. Breast 2016; 27:69-77.
Apr 4, 2016
Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trial
Apr 4, 2016
Breast 2016; 27:69-77
Schwentner Lukas, Janni Wolfgang, Kiechle Marion, Härtl Kristin, Weissenbacher Tobias, Friedl Thomas W P, Huober Jens, Scholz Christoph, Wischnik Arthur, Forstbauer Helmut, Rack Brigitte, Eichler Martin, Singer Susanne, Harbeck Nadia, Fink Visnja
more
